• PharmAust invited to apply for up to $1.8m grant funding from FightMND
  • Funding would be applied to company’s Phase 2 study of its drug to treat motor neurone disease and amyotrophic lateral sclerosis
  • Successful grant applications will be notified by July 2024

 

Special Report: FightMND, Australia’s leading not-for-profit foundation for motor neurone disease research, has invited PharmAust to submit a full grant application to help cover costs of its planned Phase 2 study due to begin in H1 2024.

The company’s planned Phase 2/3 study is a multicentre, randomised, placebo-controlled, adaptive clinical study evaluating the safety and efficacy of its monepantel (MPL) treatment in patients with Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS) over 48 weeks.

The primary aim will be to evaluate the efficacy of MPL, as compared to placebo, on MND/ALS disease progression.

Earlier this month, PharmAust (ASX:PAA) submitted a letter of intent to FightMND in response to their call for clinical study proposals aimed at academic-industry partnerships –including but not limited to – pharmaceutical, bio-therapeutic/biotechnology companies, academic institutions and universities, hospitals, and MND researchers throughout the world.

 

Up to $1.8m could be on the table

Up to $1.8 million in support from FightMND is available per grant – and a successful application could play a key role in PAA’s development of the monepantel drug.

“Gaining access to undiluted funds to help offset the costs of drug development is a goal of every biotechnology company,” PAA CEO Dr Michael Thurn said.

“FightMND has already been influential to date in the development of monepantel for MND/ALS by fully funding our initial Phase 1 study.

“Based on the potential shown to date for monepantel to provide patients with MND/ALS with a treatment benefit, we are excited at our prospects of securing further funding from FightMND for our adaptive Phase 2/3 study.”

Applications for grant funding are due by the 24 March 2024, with successful recipients to be notified in July 2024.

 

 

This article was developed in collaboration with PharmAust, a Stockhead advertiser at the time of publishing.

 

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Read MoreHealth

Featured Companies

You might be interested in